{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:31:36Z","timestamp":1780806696444,"version":"3.54.1"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Municipal Natural Science Foundation","award":["7192218, 7242210"],"award-info":[{"award-number":["7192218, 7242210"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:p>To describe clinical manifestations, toxicities, and document measures for the management of neurotoxicity of vinca alkaloids (VAs) in pediatric cases. And discuss the difference between VAs monotherapy and combination of triazoles. A retrospective and descriptive analysis of adverse drug interaction (ADR) cases, which reported to the National Center for ADR monitoring from Peking University People\u2019s Hospital from January 2010 to December 2023, was performed. We also herein present a review of the literature on neurotoxicity caused by VAs. One hundred twenty-three patients were included. Median age was 4 years (0.1\u201318 years) with 86 (70.7%) having a diagnosis of acute lymphoblastic leukemia. The median number of VAs doses administered after which the neurotoxicity occurred was 3 doses (1\u201312 doses). The median time to clinical manifestations of adverse events was 21 days (1\u2013140 days). The most common neuropathic toxicity is autonomic neuropathy, with paralytic ileus accounting for the highest proportion. More patients experienced severe neurotoxicity when treated with the combination of triazoles and VAs than with VAs monotherapy. In clinical practice, doctors and clinical pharmacists should pay attention to this adverse drug interaction. It is recommended to monitor for signs of neurotoxicity and consider the use of alternative antifungal agents in patients receiving VAs chemotherapy, in order to mitigate the occurrence of this adverse drug interaction.<\/jats:p>","DOI":"10.1097\/md.0000000000047447","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:01:13Z","timestamp":1769965273000},"page":"e47447","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effect of antifungal triazoles on vinca alkaloid neurotoxicity in pediatric patients: A retrospective case series analysis and literature review"],"prefix":"10.1097","volume":"105","author":[{"given":"Yinyu","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-1374","authenticated-orcid":false,"given":"Lin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia.","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00277-017-3144-1","article-title":"Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.","volume":"97","author":"Iurlo","year":"2018","journal-title":"Ann Hematol"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO).","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs.","volume":"9","author":"Bruggemann","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"R7-20260519","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R9-20260519","first-page":"754","article-title":"[The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)].","volume":"59","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-019-03884-5","article-title":"Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.","volume":"84","author":"Madsen","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0140-6736(95)92816-2","article-title":"Vincristine toxicity in five children with acute lymphoblastic leukaemia.","volume":"346","author":"Murphy","year":"1995","journal-title":"Lancet"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"12053","DOI":"10.1021\/bi001038r","article-title":"Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line.","volume":"39","author":"Lobert","year":"2000","journal-title":"Biochemistry"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pbc.20123","article-title":"Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor.","volume":"43","author":"Schiavetti","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/j.1875-9114.1998.tb03152.x","article-title":"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.","volume":"18","author":"Chan","year":"1998","journal-title":"Pharmacotherapy"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pbc.22399","article-title":"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.","volume":"54","author":"Jain","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-93-5-781_2","article-title":"Blindness and vincristine.","volume":"93","author":"Awidi","year":"1980","journal-title":"Ann Intern Med"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19810101)47:1<37::AID-CNCR2820470108>3.0.CO;2-8","article-title":"Transient cortical blindness secondary to vincristine therapy in childhood malignancies.","volume":"47","author":"Byrd","year":"1981","journal-title":"Cancer"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1096-911X(199803)30:3<193::AID-MPO14>3.0.CO;2-O","article-title":"Vincristine overdosage in paediatric patients.","volume":"30","author":"Stones","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1356::AID-CNCR20>3.0.CO;2-#","article-title":"Severe vincristine neuropathy in charcot-marie-tooth disease type 1A.","volume":"77","author":"Graf","year":"1996","journal-title":"Cancer"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1288\/00005537-199211000-00011","article-title":"Vincristine-induced recurrent laryngeal nerve paralysis.","volume":"102","author":"Annino","year":"1992","journal-title":"Laryngoscope"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/BF01713944","article-title":"Vincristine-induced recurrent laryngeal nerve paralysis in children.","volume":"17","author":"Tobias","year":"1991","journal-title":"Intensive Care Med"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mpo.2950170534","article-title":"Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I.","volume":"17","author":"McGuire","year":"1989","journal-title":"Med Pediatr Oncol"},{"key":"R24-20260519","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jop.1988.4.117","article-title":"Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.","volume":"4","author":"Teichmann","year":"1988","journal-title":"J Ocul Pharmacol"},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00313556","article-title":"Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology.","volume":"229","author":"Tomiwa","year":"1983","journal-title":"J Neurol"},{"key":"R26-20260519","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1542\/peds.70.2.288","article-title":"Optic atrophy induced by vincristine.","volume":"70","author":"Shurin","year":"1982","journal-title":"Pediatrics"},{"key":"R27-20260519","first-page":"68","article-title":"Bilateral vocal cord paralysis following treatment with vincristine.","volume":"46","author":"Naithani","year":"2009","journal-title":"Indian Pediatr"},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archoto.2008.514","article-title":"The natural history of vincristine-induced laryngeal paralysis in children.","volume":"135","author":"Kuruvilla","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R29-20260519","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MPH.0b013e3181a7153e","article-title":"Vincristine induced unilateral ptosis.","volume":"31","author":"Dejan","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R30-20260519","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPH.0b013e318158343b","article-title":"Vincristine-induced peripheral neuropathy and urinary bladder paralysis in a child with rhabdomyosarcoma.","volume":"30","author":"Citak","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"R31-20260519","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/pbc.20638","article-title":"Vincristine sulfate as a possible cause of optic neuropathy.","volume":"48","author":"Weisfeld-Adams","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R32-20260519","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/08880010701451327","article-title":"Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy.","volume":"24","author":"Ozyurek","year":"2007","journal-title":"Pediatr Hematol Oncol"},{"key":"R33-20260519","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pbc.20850","article-title":"Vincristine-induced bilateral vocal cord paralysis in children.","volume":"48","author":"Ahmed","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R34-20260519","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF02759902","article-title":"Vincristine induced cranial polyneuropathy.","volume":"73","author":"Bay","year":"2006","journal-title":"Indian J Pediatr"},{"key":"R35-20260519","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.mph.0000162071.75954.14","article-title":"Treatment of vincristine-induced cranial polyneuropathy.","volume":"27","author":"Duman","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R36-20260519","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pbc.10301","article-title":"Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine.","volume":"42","author":"Muller","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"R37-20260519","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mpo.10377","article-title":"Transient cortical blindness following vincristine therapy.","volume":"41","author":"Schouten","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"R38-20260519","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1460-9592.2002.00816.x","article-title":"Vincristine-induced vocal cord paralysis in an infant.","volume":"12","author":"Anghelescu","year":"2002","journal-title":"Paediatr Anaesth"},{"key":"R39-20260519","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijporl.2019.04.001","article-title":"Vincristine-induced vocal cord paresis and paralysis in children.","volume":"123","author":"Zavala","year":"2019","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R40-20260519","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3928\/01913913-20150629-01","article-title":"Vincristine-induced neuropathy presenting as ptosis and ophthalmoplegia in a 2-year-old boy.","volume":"52","author":"Palkar","year":"2015","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R41-20260519","first-page":"66","article-title":"Vincristine-induced cranial neuropathy.","volume":"8","author":"Talebian","year":"2014","journal-title":"Iran J Child Neurol"},{"key":"R42-20260519","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1752-1947-6-128","article-title":"Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report.","volume":"6","author":"Farruggia","year":"2012","journal-title":"J Med Case Rep"},{"key":"R43-20260519","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MPH.0b013e3181e01584","article-title":"Vincristine-induced vocal cord palsy: case report and review of the literature.","volume":"32","author":"Latiff","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R44-20260519","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12098-009-0254-3","article-title":"Vincristine induced neurotoxicity in cancer patients.","volume":"77","author":"Gomber","year":"2010","journal-title":"Indian J Pediatr"},{"key":"R45-20260519","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/MPH.0b013e3181d7742f","article-title":"Vincristine and intestinal pseudo-obstruction in children: report of 5 cases, literature review, and suggested management.","volume":"32","author":"Diezi","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R46-20260519","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1097\/MPH.0b013e3181d419ad","article-title":"Vincristine-induced peripheral neuropathy in a neonate with congenital acute lymphoblastic leukemia.","volume":"32","author":"Baker","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R47-20260519","doi-asserted-by":"crossref","first-page":"NP459","DOI":"10.1177\/0145561320924868","article-title":"Pediatric oncology patients with vincristine-induced recurrent laryngeal nerve palsy: two case reports and a brief review of literature.","volume":"100","author":"Tay","year":"2021","journal-title":"Ear Nose Throat J"},{"key":"R48-20260519","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/coa.13778","article-title":"Vocal cord paralysis secondary to vincristine treatment in children: a case series of seven children and literature review.","volume":"46","author":"Godbehere","year":"2021","journal-title":"Clin Otolaryngol"},{"key":"R49-20260519","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1097\/MPH.0000000000002114","article-title":"Severe vincristine-related neurotoxicity in 5 patients with pediatric acute lymphoblastic leukemia requiring discontinuation of vincristine: a description of long-term outcome.","volume":"43","author":"Egan-Sherry","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"R50-20260519","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF01697985","article-title":"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.","volume":"71","author":"Bohme","year":"1995","journal-title":"Ann Hematol"},{"key":"R51-20260519","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/088800101300002973","article-title":"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.","volume":"18","author":"Jeng","year":"2001","journal-title":"Pediatr Hematol Oncol"},{"key":"R52-20260519","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1651-2227.2001.tb03257.x","article-title":"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.","volume":"90","author":"Kamaluddin","year":"2001","journal-title":"Acta Paediatr"},{"key":"R53-20260519","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1440-1754.2003.00255.x","article-title":"Severe vincristine neurotoxicity with concomitant use of itraconazole.","volume":"39","author":"Ariffin","year":"2003","journal-title":"J Paediatr Child Health"},{"key":"R54-20260519","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.mph.0000172751.06286.5b","article-title":"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.","volume":"27","author":"Bermudez","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R55-20260519","first-page":"135","article-title":"Prolonged vincristine toxicity induced by concurrent posaconazole in a child with T-cell acute lymphoblastic leukemia.","volume":"38","author":"Alavi","year":"2013","journal-title":"Iran J Med Sci"},{"key":"R56-20260519","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1097\/MPH.0000000000001022","article-title":"Toxicity of vincristine combined with posaconazole in children with acute lymphoblastic leukemia.","volume":"40","author":"Pekpak","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"R57-20260519","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPH.0b013e31819b9d01","article-title":"Posaconazole-increased vincristine neurotoxicity in a child: a case report.","volume":"31","author":"Eiden","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R58-20260519","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/jcpt.12598","article-title":"Syndrome of inappropriate antidiuretic hormone secretion from concomitant use of itraconazole and vindesine.","volume":"43","author":"Zhou","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"R59-20260519","doi-asserted-by":"crossref","first-page":"3000605231193823","DOI":"10.1177\/03000605231193823","article-title":"Ileus induced by the combination of vinca alkaloids and posaconazole in a patient with acute lymphoblastic leukemia: a case report and literature review.","volume":"51","author":"Li","year":"2023","journal-title":"J Int Med Res"},{"key":"R60-20260519","first-page":"14","article-title":"Observation and prevention of neurotoxicity in chemotherapy on malignant tumors patients.","volume":"12","author":"Li","year":"2006","journal-title":"Int Med Health Guidance News"},{"key":"R61-20260519","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2026.44.7_suppl.193","article-title":"Chinese expert consensus on Vinca alkaloids in the treatment of malignant lymphoma.","volume":"44","author":"Wang","year":"2017","journal-title":"Chin J Clin Oncol"},{"key":"R62-20260519","first-page":"363","article-title":"Vincristine-induced seizure from drug interactions: a case report and review of literature.","volume":"16","author":"Heidari","year":"2023","journal-title":"Case Rep Oncol"},{"key":"R63-20260519","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5435\/JAAOS-D-14-00162","article-title":"Paralytic ileus in the orthopaedic patient.","volume":"23","author":"Daniels","year":"2015","journal-title":"J Am Acad Orthop Surg"},{"key":"R64-20260519","doi-asserted-by":"crossref","first-page":"e14046","DOI":"10.1111\/nmo.14046","article-title":"Postoperative ileus-AN ongoing conundrum.","volume":"33","author":"Wattchow","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"R65-20260519","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000522153","article-title":"Validity of weekly administration of carboplatin after carboplatin-induced SIADH: TWO CASE REPORTS AND LITERATURE REVIEW.","volume":"15","author":"Fujitsuka","year":"2022","journal-title":"Case Rep Oncol"},{"key":"R66-20260519","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1056\/NEJMcp066837","article-title":"Clinical practice. The syndrome of inappropriate antidiuresis.","volume":"356","author":"Ellison","year":"2007","journal-title":"N Engl J Med"},{"key":"R67-20260519","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/practneurol-2021-003194","article-title":"Posterior reversible encephalopathy syndrome (PRES): diagnosis and management.","volume":"22","author":"Triplett","year":"2022","journal-title":"Pract Neurol"},{"key":"R68-20260519","first-page":"16","article-title":"Clinical and imaging findings in childhood posterior reversible encephalopathy syndrome.","volume":"12","author":"Gungor","year":"2018","journal-title":"Iran J Child Neurol"},{"key":"R69-20260519","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fneur.2020.00194","article-title":"Clinical and MRI features of posterior reversible encephalopathy syndrome with atypical regions: a descriptive study with a large sample size.","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol"},{"key":"R70-20260519","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3892\/etm.2017.4570","article-title":"The clinical characteristics of posterior reversible encephalopathy syndrome in patients with chronic renal failure.","volume":"14","author":"Hu","year":"2017","journal-title":"Exp Ther Med"},{"key":"R71-20260519","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12883-022-02985-8","article-title":"The pathogenesis and treatment of posterior reversible encephalopathy syndrome after neuromyelitis optica spectrum disorder: a case report and literature review.","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Neurol"},{"key":"R72-20260519","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12902-022-01109-0","article-title":"Pheochromocytoma manifesting as cortical blindness secondary to PRES with associated TMA: a case report and literature review.","volume":"22","author":"Patel","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R73-20260519","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMra2114482","article-title":"Posterior reversible encephalopathy syndrome.","volume":"388","author":"Geocadin","year":"2023","journal-title":"N Engl J Med"},{"key":"R74-20260519","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British society for medical mycology.","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R75-20260519","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the society of infectious diseases pharmacists: endorsed by the mycoses study group education and research consortium.","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"Suppl 2","key":"R76-20260519","first-page":"S63","article-title":"Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment.","volume":"24","author":"Islam","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"R77-20260519","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.3390\/ijms22084112","article-title":"Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment.","volume":"22","author":"Triarico","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R78-20260519","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mpo.2950100202","article-title":"The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer.","volume":"10","author":"Nelson","year":"1982","journal-title":"Med Pediatr Oncol"},{"key":"R79-20260519","first-page":"417","article-title":"Severe neuropathic pain with concomitant administration of vincristine and posaconazole.","volume":"23","author":"Lin","year":"2018","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R80-20260519","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/pbc.21918","article-title":"Treatment of intestinal and hepatic mucormycosis in an immunocompromized child.","volume":"52","author":"Luer","year":"2009","journal-title":"Pediatr Blood Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:04:33Z","timestamp":1779195873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047447","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-08-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}